###### Significance of this study

What is already known on this subject?
======================================

-   Bariatric surgery, particularly the malabsorptive type, alters the gut microbiota and host metabolism.

-   Pregnancy following bariatric surgery, especially a malabsorptive procedure, is associated with a reduced prevalence of maternal gestational diabetes and increased prevalence of small for gestational age babies.

What are the new findings?
==========================

-   We demonstrated that malabsorptive surgery-induced changes in the maternal gut microbiota persist throughout pregnancy compared with pregnancies with similar maternal body mass index but no history of such surgery, and may have a trans-generational impact.

-   Gut microbial changes in malabsorptive patients are associated with increased excretion of protein putrefaction metabolites during pregnancy.

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   The impact of maternal malabsorption on fetal health warrants further investigation to determine the most appropriate type of weight loss surgery for women of reproductive age.

Introduction {#s1}
============

Currently more than a third of women are classified as overweight or obese[@R1] with obesity reaching epidemic levels globally. Obesity is associated with a number of adverse metabolic effects resulting in cardiovascular disease, metabolic syndrome, diabetes and cancer.[@R2] Bariatric surgery (BS) has proven a successful treatment modality for lasting weight loss and has been shown to reduce obesity-related morbidity and mortality.[@R3] Altered **b**ile flow, **r**eduction in gastric capacity, **a**natomical gut rearrangement and altered nutrient flow, **v**agal manipulation and modulation of **e**nteric gut hormones, collectively referred to as the BRAVE effects,[@R3] have been proposed to contribute to the mechanisms of weight loss and diabetes resolution in bariatric patients. There are two main types of BS: the restrictive (RES) procedures such as gastric banding and sleeve gastrectomy, which reduce the stomach size, and the malabsorptive/mixed (MAL) type, such as bilio-pancreatic diversion and Roux-en-Y-gastric bypass, which aim to decrease caloric absorption.[@R6] BS has been shown to impact metabolic profiles reflecting altered metabolism and changes in the gut microbiome that play a role in improved lipid and glucose metabolism.[@R7] The contribution of the gut mictobiota to host metabolism and metabolic control is well-established. Microbes degrade dietary components that are undigested by the host, convert dietary molecules into bioactive metabolites, influence host response to drugs and participate in many homeostatic processes and signalling pathways.[@R12] However, the mechanisms by which BS confers metabolic benefit and the potential role of the microbiome in achieving this are poorly understood.

Evidence continues to accumulate that pregnancy post-BS is associated with lower prevalence of gestational diabetes mellitus (GDM) and large for gestational age neonates but higher risk of small for gestational age neonates and late preterm delivery compared with pregnancies in obese women without a previous BS.[@R14] To investigate the impact of previous BS on maternal phenotype during pregnancy, we adopted a longitudinal metabolic (serum and urine) and gut bacterial (faeces) profiling strategy using proton nuclear magnetic resonance (^1^H NMR) spectroscopy and 16S rRNA gene amplicon sequencing, respectively, to characterise women with previous BS (RES and MAL) throughout the course of their pregnancy. Profiles were compared against women with similar early pregnancy body mass index (BMI) and no history of BS (NBS). For a subset of the cohort, we also characterise neonatal cord serum and urine metabolomes to assess potential trans-generational metabolic effects of BS.

Methods {#s2}
=======

Study population, sampling and clinical data {#s2-1}
--------------------------------------------

The population is part of an ongoing prospective cohort study investigating the impact of maternal BS on perinatal outcomes. All women gave written, informed consent for their data and samples to be used. Pregnant women with (n=47) and without (n=118) previous BS were recruited from May 2015 to April 2017 at Chelsea and Westminster Hospital (London, UK) as previously described.[@R15] Women were seen at five time points during pregnancy (**T1**: 11^+0^--14^+0^, **T2**: 20^+0^--24^+0^, **T3**: 28^+0^--30^+0^, **T4**: 30^+0^--33^+0^ and **T5**: 35^+0^--37^+6^ weeks gestation) and within 72 hours of delivery (**T6**). Maternal blood (serum) and urine samples were collected at each visit while faecal samples were requested at the T1, T2 and T4 visits (see [online supplementary figure S1 and table S1](#SP1){ref-type="supplementary-material"}). A full oral glucose tolerance test (2 hour, 75 g) was conducted at T3 and maternal insulin resistance was calculated using the homeostatic model assessment for insulin resistance (HOMA-IR=fasting serum insulin (µU/L) × fasting glucose (mmol/L)/22.5). Estimated fetal weight was calculated by trans-abdominal ultrasound scans at T2, T4 and T5. At T6, birth weight was recorded, percentiles for the gestation were calculated and, where possible, neonatal samples (cord serum and urine) were collected. All samples were stored at −80°C for future analysis. For the study population, women with diagnosis of type 2 diabetes mellitus or GDM (due to the effect of diabetes on the metabolic profile) and those that had a miscarriage were excluded. Only NBS participants with a BMI of 25--50 kg/m^2^ at T1 were included to match the BMI range of the included bariatric patients at T1.
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Metabolic profiling of biofluid samples {#s2-2}
---------------------------------------

Serum and urine samples were prepared according to an established protocol.[@R16] ^1^H NMR spectra were acquired on a Bruker 600 MHz spectrometer (Bruker BioSpin) following a published method[@R16] (see [online supplementary methods](#SP2){ref-type="supplementary-material"} for further detail). Methodology for preprocessing of spectral data is described in [online supplementary methods](#SP2){ref-type="supplementary-material"}. Multivariate modelling of the spectral data was performed in the software package SIMCA V.14.1 (Sartorius Stedim Biotech). Principal component analysis (PCA) was used to assess variation in metabolic profiles over all time points and to identify extreme outliers to exclude from supervised models for each time point. Orthogonal partial least squares discriminant analysis (OPLS-DA) was used to identify spectral variables (relating to specific chemical compounds) that contributed to discrimination of clinical classes (pairwise comparisons between NBS, MAL and RES groups) at each time point. From the discriminatory NMR peaks, metabolite identities were confirmed using statistical tools,[@R17] 2D NMR experiments and by spiking in authentic standards (see [online supplementary methods](#SP2){ref-type="supplementary-material"}). Relative concentrations of each discriminatory metabolite were calculated by integrating a representative peak of that metabolite. Downstream analysis was performed in the R software environment.[@R19] For each discriminatory metabolite identified in the cross-sectional analysis, time series curves were generated through a spline-fitting method implemented in 'santaR' (see [online supplementary methods](#SP2){ref-type="supplementary-material"}) to visualise their behaviour in different groups over the pregnancy time course. Individuals with at least five data points were included. Correlation analysis including partial correlation to adjust for confounders is detailed in the [online supplementary methods](#SP2){ref-type="supplementary-material"} along with a list of all R packages used. Missing data were excluded from calculations. All p values were adjusted (p~adj~) where necessary to control for the false discovery rate according to the Benjamini-Hochberg method.[@R20] An alpha of 0.05 was used for p and p~adj~ values.
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Gut bacterial community profiling {#s2-3}
---------------------------------

Stool samples were randomised for processing and DNA was extracted (see [online supplementary methods](#SP2){ref-type="supplementary-material"}) using the PowerLyzer PowerSoil DNA Isolation Kit (Mo Bio). 16S rRNA gene amplicon sequencing targeting the V1-V2 regions was performed on the Illumina MiSeq platform as previously described.[@R21] Raw reads were processed in the R software environment[@R19] following a published workflow[@R22] which includes amplicon denoising implemented in 'DADA2'.[@R23] See [online supplementary methods](#SP2){ref-type="supplementary-material"} for full details. Functions in the 'vegan' R package were used to calculate Shannon Diversity Indices (α-diversity) on data rarefied to the minimum sequencing depth and Bray-Curtis dissimilarity (β-diversity) on log-transformed data (pseudocount of 1 added to each value). Significance of group separation in β-diversity was assessed by permutational multivariate analysis of variance. Changes in relative abundance were tested at each taxonomic rank from phylum to genus using the Mann-Whitney U test while differentially abundant 16S rRNA gene sequences were identified using 'DESeq2'.[@R24] For 'DESeq2' analysis, data were pooled for each individual rather than analysing distinct time points.

Integrative analysis of metabolic and taxonomic data {#s2-4}
----------------------------------------------------

Relationships between the serum, urine and faecal data sets were modelled using the DIABLO method in 'mixOmics'.[@R25] This is a multi-block latent variable-based approach which aims to identify concordance between multiple data sets. Metabolites significant throughout the time course (serum: leucine, isoleucine, isobutyrate, d-β-hydroxybutyrate; urine: phenylacetylglutamine (PAG), *p*-cresol sulfate (PCS), indoxyl sulfate (IS), *p*-hydroxyphenylacetate (PHPA), unknown, α-ketoisovalerate, creatinine) and a subset of bacterial genera (log-transformed; selected using the least absolute shrinkage and selection operator (LASSO) penalisation method implemented in 'mixOmics') were modelled. Sampling points for each individual, where matching microbiome and metabolite data were obtained (T1, T2 and T4), were included in the model.

Results {#s3}
=======

Characteristics of the study participants {#s3-1}
-----------------------------------------

Of the 165 women enrolled in the study, 54 were excluded from longitudinal profiling due to BMI (n=36), diagnosis of diabetes (n=16), miscarriage (n=1) or withdrawal from the study (n=1). The final study population included 111 women (NBS n=70, RES n=16, MAL n=25) who contributed 491 maternal urine, 394 maternal blood, 68 maternal stool ([online supplementary figure S1](#SP1){ref-type="supplementary-material"}), 54 cord blood and 28 neonatal urine samples ([online supplementary table S1](#SP1){ref-type="supplementary-material"}). Two women (RES n=1, MAL n=1) contributed only neonatal samples. All women in the MAL group had a previous gastric bypass while the RES group had gastric banding (n=8) or sleeve gastrectomy (n=8). Maternal demographics, pregnancy characteristics and outcomes of the study population ([online supplementary table S2](#SP1){ref-type="supplementary-material"}) were consistent with our earlier report.[@R15] Compared with the NBS group, women with a previous BS were on average 3.7 years older and, especially those with a MAL procedure, had lower insulin resistance at T3 and delivered smaller babies earlier ([online supplementary table S2](#SP1){ref-type="supplementary-material"}). Among the BS group, women with a previous MAL procedure had a higher pre-surgery BMI compared with those with a previous RES procedure.

Metabolic differences in maternal and neonatal serum metabolomes associated with bariatric surgery {#s3-2}
--------------------------------------------------------------------------------------------------

Clear differences between the serum metabolic profiles of MAL, but not RES, participants and NBS participants were detected in the third trimester of pregnancy (time points T4 and T5; [online supplementary table S3](#SP1){ref-type="supplementary-material"}) as evidenced by the OPLS-DA models. The serum metabolic profiles associated with BS at the time of labour and in the first and second trimesters could not be differentiated from the control group. Serum samples obtained from MAL patients contained lower concentrations of unsaturated lipids (CH=CH, δ 5.31 (m)) at T5 and the lipids group corresponding to C=CCH~2~C=C (δ 2.79 (m)) at both T4 and T5 ([online supplementary figure S2](#SP1){ref-type="supplementary-material"}) compared with the NBS group. Other metabolic differences between the MAL and NBS groups included ([online supplementary table S4](#SP1){ref-type="supplementary-material"}) *N*-acetyl glycoprotein (GlycA), leucine, isoleucine, isobutyrate (decreased in MAL) and glutamine, d-β-hydroxybutyrate (increased in MAL). The behaviour of these metabolites throughout the pregnancy period was investigated further using time series analysis to model individual metabolites. Serum leucine, isoleucine and isobutyrate concentrations were significantly lower in MAL (n=12; NBS n=34) throughout the time course ([figure 1A](#F1){ref-type="fig"}), whereas increases in d-β-hydroxybutyrate were associated with the last few weeks of pregnancy and delivery. GlycA and glutamine were not significantly changed in MAL during pregnancy. Significance of the differential serum metabolite concentrations at each time point is shown in [online supplementary figure S3A](#SP1){ref-type="supplementary-material"}. There was no significant difference between NBS and RES participants at any time point ([online supplementary table S5](#SP1){ref-type="supplementary-material"}). Although OPLS-DA and time series modelling showed clear evidence that previous BS impacted on the metabolic profiles, PCA indicated that the greatest metabolic variation in plasma composition was due to the changes over time during pregnancy, irrespective of surgery, with samples collected at T1 being markedly different from those obtained at later time points in the pregnancy ([online supplementary figure S4](#SP1){ref-type="supplementary-material"}). Thus no inherent structure associated with study group, age or BMI was evident in the ^1^H NMR maternal serum data. No differences in the metabolic profiles of cord serum from neonates in each study group were detected ([online supplementary table S3](#SP1){ref-type="supplementary-material"}).

![Modelling of metabolite concentrations. (A) Time series analysis of discriminatory metabolites with lines representing group mean curves while shaded areas denote 95% confidence bands. Malabsorptive (MAL, blue) patients relative to No bariatric surgery (NBS, purple) controls. (B) Relative concentration of phenylacetylglutamine (PAG) is increased in neonatal urine from the MAL group compared with the NBS or restrictive (RES) groups. NMR peak integrals are reported in arbitrary units (a.u.). \**P*\<0.05 (Mann-Whitney U test); GlycA, *N-*acetyl glycoprotein; IS, indoxyl sulfate; PCS, *p*-cresol sulfate; PHPA, *p*-hydroxyphenylacetate.](gutjnl-2019-319620f01){#F1}

Surgery-associated metabolic differences in maternal and neonatal urine metabolomes {#s3-3}
-----------------------------------------------------------------------------------

Similar to the serum samples, PCA models indicated that the metabolic variation driven by temporal changes throughout pregnancy was stronger than that associated with study group, age or BMI ([online supplementary figure S4](#SP1){ref-type="supplementary-material"}). Urine samples collected at delivery (T6) clearly differed from those taken at any other time point during pregnancy. In addition to endogenous changes, drug metabolites of paracetamol as well as mannitol, a common ingredient in drug tablet coating, were detected in urine obtained at T6. Outliers identified from PCA models at each time point were samples containing high concentrations of glucose or drug metabolites and were excluded from subsequent supervised models ([online supplementary table S3](#SP1){ref-type="supplementary-material"}). Based on the OPLS-DA models, no significant differences were identified between NBS and RES groups or between RES and MAL groups at any of the six time points; however, urine metabolic profiles of MAL patients were significantly altered compared with the NBS group as early as T1 and this difference persisted throughout pregnancy ([online supplementary table S3](#SP1){ref-type="supplementary-material"}). The strongest discriminatory metabolites ([online supplementary table S4](#SP1){ref-type="supplementary-material"} and [online supplementary figure S5](#SP1){ref-type="supplementary-material"}) contributing to the differences between MAL and NBS groups were host-gut bacterial co-metabolites PAG, PCS, IS, PHPA, as well as an unidentified aromatic metabolite (unknown) with structural similarities to PCS (based on both ^1^H and ^13^C shifts; [online supplementary figure S6](#SP1){ref-type="supplementary-material"}). These metabolites were significantly elevated in MAL (n=14; NBS n=50) patients during pregnancy ([figure 1A](#F1){ref-type="fig"}). Creatinine and α-ketoisovalerate were present in lower concentrations in MAL patients; methylmalonate and valine were not significantly associated with the MAL group over the time course ([figure 1A](#F1){ref-type="fig"}) but were significantly lower in MAL patients at specific time points ([online supplementary figure S3B](#SP1){ref-type="supplementary-material"}). None of these metabolites were significantly changed in the RES group after correcting for multiple hypothesis tests ([online supplementary table S5](#SP1){ref-type="supplementary-material"}). Interestingly, when the RES group was divided into gastric banding (purely mechanical) and sleeve gastrectomy (removal of part of the stomach with metabolic effects), patients with a sleeve tended to have higher PAG and PCS than patients with a band ([online supplementary figure S7](#SP1){ref-type="supplementary-material"}). Maternal urine samples collected at T6 could not be discriminated for any pairwise comparison by OPLS-DA ([online supplementary table S3](#SP1){ref-type="supplementary-material"}). However PAG, the metabolite with the largest effect size in maternal samples, retained significance in the offspring's urine at T6 ([figure 1B](#F1){ref-type="fig"}). The relative concentration of PAG was significantly increased in babies born from MAL mothers (n=4) compared with babies born from RES (n=6, p=0.04) and NBS (n=18, p=0.021) mothers, mirroring the difference observed between the MAL and NBS maternal samples.

![Gut bacterial alterations in malabsorptive patients. (A) Comparison of Shannon diversity between malabsorptive (MAL) and no bariatric surgery (NBS) groups at 11--14 weeks (T1), 20--24 weeks (T2) and 30--33 weeks (T4) gestation. (B) Principal coordinates analysis of Bray-Curtis dissimilarities between MAL (blue) and NBS (purple) during pregnancy (T1: circle, T2: triangle, T4: square). P value obtained from permutational multivariate analysis of variance test. (C) Taxa that exhibited differential abundance (Mann-Whitney U test; p~adj~\<0.05) at more than one time point are plotted. Values are reported in [online supplementary table S6](#SP1){ref-type="supplementary-material"}. \*\*P\<0.01 (Mann-Whitney U test); NS, not significant.](gutjnl-2019-319620f02){#F2}

Taxonomic changes in the maternal gut microbiota of MAL patients {#s3-4}
----------------------------------------------------------------

To support the finding of altered microbiota-associated metabolites in MAL patients detected by ^1^H NMR spectroscopy, faecal microbiome compositions from a subset of the cohort were analysed. A total of 68 stool samples representing 39 mothers (NBS n=25, MAL n=14) were studied. After excluding one maternal NBS sample due to low sequencing depth (2181 reads), the mean number of high-quality, paired-end 16S rRNA gene amplicon sequences per sample was 22 405 (±5535 SD) with a minimum sequencing depth of 12 967.

Women with a previous MAL surgery exhibited greater α-diversity, or a higher number of distinct taxa with more even distributions, compared with the NBS group but this was only statistically significant in the third trimester of pregnancy ([figure 2A](#F2){ref-type="fig"}). β-diversity analysis comparing pairwise dissimilarities between samples revealed that MAL patients had a distinct (p=0.001) gut microbiota from the NBS group throughout pregnancy ([figure 2B](#F2){ref-type="fig"}). MAL patients could be distinguished by an increase in relative abundance of *Escherichia/Shigella, Streptococcus* and *Enterococcus* genera and these changes manifested at all higher taxonomic ranks ([figure 2C](#F2){ref-type="fig"}). Relative increases in abundances of *Rothia* and its family *Micrococcaceae* were also observed. *Anaerostipes* was the only genus found in significantly lower relative abundance in the MAL group at multiple time points. Only taxa that exhibited differential abundance in the MAL group at more than one time point were included in [figure 2C](#F2){ref-type="fig"}, but taxa displaying differences between groups at a single time point during pregnancy are detailed in [online supplementary table S6](#SP1){ref-type="supplementary-material"}. Differential abundance at the amplicon sequence level was investigated for sequences assigned to the genera *Streptococcus, Enterococcus*, *Escherichia/Shigella* and *Rothia*. Species assignments were compared against SILVA[@R26] and RDB[@R27] databases. From the 25 16S rRNA gene sequences (*Escherichia/Shigella* n=11, *Streptococcus* n=12, *Enterococcus* n=1 and *Rothia* n=1) found in significantly higher abundance in MAL patients ([online supplementary table S7](#SP1){ref-type="supplementary-material"}), the following species were identified: *Escherichia coli, Streptococcus salivarius, Streptococcus vestibularis, Streptococcus mutans* and *Streptococcus parasanguinis*.

Integrative analysis of phenotypes {#s3-5}
----------------------------------

To determine if the observed MAL signatures were complementary across the data sets, an integrative approach was used to model the bacterial (n=68) and metabolic (serum n=60; urine n=66) data together. Clinical classes could be discriminated on the first component of the model for both urine and faecal data sets while this difference was not apparent in the serum data ([figure 3A](#F3){ref-type="fig"}). Urine PAG, PCS, and IS concentrations were highly correlated and had the highest contribution to the model followed by leucine, isoleucine (also highly correlated) and isobutyrate ([figure 3B](#F3){ref-type="fig"}). PAG, PCS and IS were most correlated with *Streptococcus, Enterococcus*, *Escherichia/Shigella*, *Rothia* and *Holdemanella* ([figure 3C](#F3){ref-type="fig"}). Variables in this cluster also had a strong negative correlation with serum leucine, isoleucine and isobutyrate. *Anaerostipes*, the only genus that decreased in abundance in the MAL group, was negatively correlated with PAG, PCS and IS but positively correlated with leucine, isoleucine and isobutyrate ([figure 3C](#F3){ref-type="fig"}).

![Integration of serum, urine and faecal profiles. (A) Scores plots showing samples from each data set projected in latent space. Clinical classes are discriminated along component 1. (B) Variables are plotted (coloured by biofluid) where each point represents the Pearson correlation between that variable and each component. High correlations with either component (\|r\|≥0.5) are BOLD and labelled. (C) Pearson correlations (\|r\|≥0.5) between variables in different data sets along component 1 are plotted. NBS, no bariatric surgery; MAL, malabsorptive; alpha-KIV, α-ketoisovalerate; D-beta-HB, d-β-hydroxybutyrate; IS, indoxyl sulfate; PAG, phenylacetylglutamine; PCS, *p*-cresol sulfate; PHPA, *p*-hydroxyphenylacetate.](gutjnl-2019-319620f03){#F3}

Metabolic profile and clinical outcomes {#s3-6}
---------------------------------------

Spearman's correlation coefficients (ρ) were calculated to assess the relationships between relative concentrations of maternal metabolites and clinical measurements (maternal: fasting insulin, fasting glucose and HOMA-IR measured at T3; neonatal: estimated fetal weight (measured at T2, T4 and T5) or birth weight percentiles, and gestational age at delivery). Throughout pregnancy, urinary host-microbial co-metabolites PAG and PCS were negatively associated with maternal HOMA-IR and fasting insulin while the branched-chain amino acids (mainly at T2) had a positive correlation ([figure 4](#F4){ref-type="fig"}). PAG and PCS relative concentrations at T2, IS and unknown at T5, and IS and PAG at T6 were also negatively correlated with the weight percentiles of the babies at the corresponding time points. Partial correlations controlling for the effect of maternal age and BMI on maternal measurements as well as the effect of maternal age, BMI and HOMA-IR on birthweight percentile are reported in [online supplementary table S8](#SP1){ref-type="supplementary-material"}, but these confounders did not alter the overall results. Importantly, the concentrations of these metabolites did not correlate ([online supplementary figure S8](#SP1){ref-type="supplementary-material"}) with percentage of weight lost or time interval between BS and conception (which ranged from 12 months to 11 years in our cohort) in MAL patients, suggesting that the phenotype is persistent.

![Relative concentrations of metabolites correlate with maternal insulin resistance and fetal/birth weight. Spearman's correlations between clinical measurements (red) and metabolite relative concentrations. Correlations plotted are significant (p~adj~\<0.05). Values are reported in [online supplementary table S8](#SP1){ref-type="supplementary-material"}. Negative correlations are denoted by dashed lines. Urine metabolites are denoted by black borders. FW/BW, estimated fetal weight or birth weight; Ile, isoleucine; IS, indoxyl sulfate; Leu, leucine; MFI, maternal fasting insulin; MIR, maternal HOMA-IR; PAG, phenylacetylglutamine; PCS, *p*-cresol sulfate.](gutjnl-2019-319620f04){#F4}

Discussion {#s4}
==========

Our results demonstrate that pregnancies following a MAL bariatric procedure are characterised by altered maternal and neonatal metabolic profiles compared with pregnancies without such surgery. In particular, women with previous MAL surgery had lower serum concentrations of branched-chain amino acids (leucine and isoleucine) and branched-chain fatty acids (isobutyrate) and excreted higher concentrations of urinary host-microbial co-metabolites of protein putrefaction (PAG, PCS, IS and PHPA). This signature was correlated with a shift in the gut microbiota which included increases in relative abundance of bacterial genera *Enterococcus*, *Streptococcus*, *Escherichia*/*Shigella* and *Rothia* as well as a decrease in *Anaerostipes*. The observed MAL-associated changes in metabolism were also inversely associated with maternal insulin resistance and the offspring's weight, suggesting that a previous MAL surgery may have both beneficial and detrimental effects on pregnancy. With regard to the RES group, we posit these patients, especially those with a previous sleeve gastrectomy, represent an intermediate phenotype due to the lower risk of malabsorption imposed by these procedures and less extreme changes to the gastrointestinal environment which would likely result in lesser alterations in the gut microbiome.[@R28]

Our results assessing the influence of BS on the maternal faecal microbiome composition are consistent with previous findings in non-pregnant individuals where MAL, but not RES, surgery resulted in increased relative abundances of *Bacilli* and *Gammaproteobacteria* (including genera *Enterococcus*, *Streptococcus* and *Escherichia*) as well as associated faecal metabolites[@R28]; abundances of both classes positively correlated with products of protein fermentation. Studies consistently show a gut bacterial signature of facultative anaerobes and oral-associated bacteria in BS (mainly MAL) patients with an increase in relative abundance of enterobacteria being the most consistent bacterial marker across multiple studies in both humans[@R7] and animals.[@R11] This shift in gut microbial community structure is believed to be, at least partially, a result of the increased oxygen and pH in the digestive tract following the anatomical rearrangement of a MAL surgery.[@R30] Enterobacteria are Gram-negative and generally present in very low densities (\<\<10^8^ CFU/g) in the normal gut, but increased abundances of these bacteria, some of which are known pathogens, have been associated with both inflammatory bowel disease and colon cancer.[@R33] This underscores the need for understanding the mechanisms by which the altered bariatric microbiome can impact on maternal and neonatal metabolism and downstream health.

Increased concentrations of urinary microbial-associated metabolites following MAL BS have been reported in animals[@R11] and in one human study with only two bariatric patients.[@R9] Carbohydrates are the preferred source of energy for microbes inhabiting the large intestine.[@R35] However, we hypothesise that the MAL condition not only changes the gastrointestinal environment resulting in an altered microbial community but also results in more undigested protein reaching the large intestine[@R36] and both of these factors likely contribute to the shift from carbohydrate to protein metabolism. Fermentation of protein by gut bacteria, or putrefaction, in the colon is generally considered detrimental to health.[@R37] Gut bacterial metabolism of aromatic amino acids (phenylalanine, tyrosine and tryptophan) results in the production of phenols and indoles,[@R38] which are inflammatory and potentially toxic compounds.[@R39] Bacterial enzymes are necessary for metabolism of phenylalanine and tyrosine to phenolic compounds phenylacetate and *p*-cresol, respectively, and for the metabolism of tryptophan to indole. Indole and *p*-cresol are sulfated to IS and PCS, respectively, prior to excretion while phenylacetate is converted to PAG by host metabolism. PHPA is an intermediate in the tyrosine degradation pathway but is also formed from phenylacetate.[@R38] *Enterococcus* spp. contain enzymes necessary for both phenylalanine and tyrosine metabolism; *E. coli* is involved in tyrosine metabolism.[@R41] Both species are also known as indole producers.[@R42] Although *Streptococcus* may not be directly involved in the formation of these metabolites, it does have proteolytic activity[@R43] and could contribute to the observed phenotype by making amino acids available from dietary protein. To our knowledge, this is the first report of upregulation of host-microbe co-metabolism of aromatic amino acids post-MAL surgery in humans. Previous reports have shown that the gut microbiota shifts to protein putrefaction after a MAL BS[@R10] but, having focused on faecal samples, the host component of these pathways was overlooked. Lacking dietary data, we cannot exclude the possibility that the MAL metabolic phenotype results from increased protein intake. However, reports of protein malnutrition and protein intolerance post-BS[@R44] suggest that high protein intake is unlikely in these patients. An inverse association between PAG/PCS and BMI has been reported although the relationship between adipiosity and the gut microbiota is still under debate.[@R46] Other reports, in agreement with our data, have identified decreased concentrations of branched-chain amino acids in non-pregnant BS patients which supports our hypothesis that protein metabolism is altered in these individuals. Branched-chain amino acids have previously been linked to insulin resistance associated with obesity.[@R47]

Our data suggest that PAG and PCS, or their respective metabolic pathways, are also associated with reduction in maternal insulin resistance following BS. We are aware of recent discussion surrounding the suitability of oral glucose tolerance testing in bariatric patients and have since revised our methods. In spite of this caveat, it is conceivable that the gut microbiota plays a role in insulin resistance.[@R49] Our finding of an inverse correlation between maternal urinary host-microbial co-metabolites and fetal/birth weight indicates that the maternal metabolic changes may also be related to the risk of these women delivering small for gestational age neonates. Although malnutrition resulting from maternal malabsorption likely contributes to reduced fetal growth, the downstream metabolic consequences of malabsorption also warrant further investigation given the potential toxicity of the final metabolic products. It has also been shown that higher urinary concentrations of PCS are indicative of reduced sulfation capacity in the host, which presents significant competition for similar reactions, namely acetaminophen detoxification, which also require sulfation prior to excretion.[@R52] Pharmacokinetics in these patients should be investigated, especially during pregnancy, given that MAL patients have higher urinary concentrations of two sulfated compounds (PCS and IS).

Pregnancy has been shown to induce substantial time-dependent alterations in physiology and metabolism[@R53] under the constantly changing physiological demand as the mother responds to the needs of the growing fetus. Nevertheless, the systematic effect of BS on the metabolic profiles is superimposed on the changing metabolic landscape and can be clearly observed in the metabolic phenotypes. In particular, GlycA, a metabolite associated with systemic inflammation, increased during the first two trimesters but remained lower in MAL patients during the third trimester indicating that these women have a lower grade of pregnancy-related inflammation compared with obese women without BS.[@R50] Drastic metabolic changes could also be seen at the time of delivery in all groups which is likely due to the metabolic consequences of the labour process and masked surgery-related differences.[@R56] Intriguingly, despite prophylactic administration of antibiotics (given to 59% of the women at delivery), PAG was detected in the neonatal urine soon after birth and in significantly higher concentration in those born from women with previous MAL surgery compared with the offspring of the NBS women. Although this result should be treated with caution due to the low number of newborns enrolled in the study, it suggests transfer of the modified maternal profile to the offspring. Further independent studies are required to validate the generalisability of this observation with longer-term follow-up of the infants to determine whether this neonatal metabolic phenotype is maintained and how it impacts their future risk of obesity and diabetes. BS is not an appropriate intervention at population scale but identification of beneficially altered physiology may allow for development of targeted interventions aimed at specifically modulating key pathways.
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